And another kind of “drug deal”
By Phil Mattera for the Dirt Diggers Digest

The other quid pro quo relates to the pharmaceutical industry, which has been the subject of a seemingly never-ending scandals about financial inducements given to healthcare professionals.
The most significant recent case
involves a company called Avanir Pharmaceuticals, which had to pay more than $115 million to resolve
allegations that it paid kickbacks to physicians to get them to prescribe its
drug Nuedexta for uses not approved as safe by the Food and Drug
Administration.
Among those uses were the treatment
of behaviors associated with dementia among residents of long-term care
facilities. Nuedexta was tested and approved for patients exhibiting what is
known as pseudobulbar affect (PBA) — involuntary, sudden, and frequent episodes
of laughing or crying that occur secondary to a neurologic disease or brain
injury.
The case against Avanir included
allegations that physicians receiving its payments ended up putting large
numbers of patients on Nuedexta who showed no symptoms of PBA, exposing them to
unknown risks.
The Justice Department regarded
Avanir’s behavior to be serious enough to warrant criminal charges, but like in
so many other cases, the company was offered a deferred prosecution agreement
that allowed it to buy its way out of full legal jeopardy by paying criminal
penalties of nearly $13 million.